ZOMETA® – Threat Of Skeletal-Related Events From Bone Metastases From Multiple Myeloma

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

Page

1 2

Bone involvement is a major concern for patients with multiple myeloma

70% to 95% of patients with advanced multiple myeloma will develop bone lesions,
which may lead to bone complications or skeletal-related events (SREs)^1*
51% of patients with multiple myeloma and osteolytic disease will develop an SRE
without treatment²

*SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia.³

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.